Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Bareiss PM, Paczulla A, Wang H, et al. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res. 2013;173(17):5544–5555.
   PubMed Web of Science ®Google Scholar
• Wang W, Yang J, Xiang YY, et al. Overexpression of hsa-miR-320 is associated with invasion and metastasis of ovarian cancer. J Cell Biochem. 2017;118(11):3654–3661.
   PubMed Web of Science ®Google Scholar
• Alimujiang A, Khoja L, Wiensch A, et al. "I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival. Gynecol Oncol. 2019;155(3):461–467.
   PubMed Web of Science ®Google Scholar
• Kleih M, Bopple K, Dong M, et al. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):851.
   PubMedGoogle Scholar
• McGuire WP, 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer. 2003;89 (Suppl 3):S3–S8.
   PubMedGoogle Scholar
• Pieterse Z, Amaya-Padilla MA, Singomat T, et al. Ovarian cancer stem cells and their role in drug resistance. Int J Biochem Cell Biol. 2019;106:117–126.
   PubMed Web of Science ®Google Scholar
• Dai X, Zhang S, Zaleta-Rivera K. RNA: interactions drive functionalities. Mol Biol Rep. 2020;47(2):1413–1434.
   PubMed Web of Science ®Google Scholar
• Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3(10):1113–1121.
   PubMed Web of Science ®Google Scholar
• Smillie CL, Sirey T, Ponting CP. Complexities of post-transcriptional regulation and the modeling of ceRNA crosstalk. Crit Rev Biochem Mol Biol. 2018;53(3):231–245.
   PubMed Web of Science ®Google Scholar
• Chen B, Huang S. Circular RNA: an emerging non-coding RNA as a regulator and biomarker in cancer. Cancer Lett. 2018;418:41–50.
   PubMed Web of Science ®Google Scholar
• Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol Ther. 2018;187:31–44.
   PubMed Web of Science ®Google Scholar
• Vincent HA, Deutscher MP. Substrate recognition and catalysis by the exoribonuclease RNase R. J Biol Chem. 2006;281(40):29769–29775.
   PubMed Web of Science ®Google Scholar
• Zhang M, Xia B, Xu Y, et al. Circular RNA (hsa_circ_0051240) promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLK4 axis. Artif Cells Nanomed Biotechnol. 2019;47(1):1224–1233.
   PubMed Web of Science ®Google Scholar
• Zhang N, Jin Y, Hu Q, et al. Circular RNA hsa_circ_0078607 suppresses ovarian cancer progression by regulating miR-518a-5p/FAS signaling pathway. J Ovarian Res. 2020;13(1):64.
   PubMed Web of Science ®Google Scholar
• Xia W, Qiu M, Chen R, et al. Circular RNA has_circ_0067934 is upregulated in esophageal squamous cell carcinoma and promoted proliferation. Sci Rep. 2016;6:35576.
   PubMed Web of Science ®Google Scholar
• Hu C, Wang Y, Li A, et al. Overexpressed circ_0067934 acts as an oncogene to facilitate cervical cancer progression via the miR-545/EIF3C axis. J Cell Physiol. 2019;234(6):9225–9232.
   PubMed Web of Science ®Google Scholar
• Wang JM, Li XJ, Wang J. Circular RNA circ_0067934 functions as an oncogene in breast cancer by targeting mcl-1. Eur Rev Med Pharmacol Sci. 2020;24(13):7214.
   PubMed Web of Science ®Google Scholar
• Changjun L, Feizhou H, Dezhen P, et al. MiR-545-3p/MT1M axis regulates cell proliferation, invasion and migration in hepatocellular carcinoma. Biomed Pharmacother. 2018;108:347–354.
   PubMed Web of Science ®Google Scholar
• Li H, Liu F, Qin W. Circ_0072083 interference enhances growth-inhibiting effects of cisplatin in non-small-cell lung cancer cells via miR-545-3p/CBLL1 axis. Cancer Cell Int. 2020;20:78.
   PubMed Web of Science ®Google Scholar
• Li H, Xiao N, Li Z, et al. Expression of inorganic pyrophosphatase (PPA1) correlates with poor prognosis of epithelial ovarian cancer. Tohoku J Exp Med. 2017;241(2):165–173.
   PubMed Web of Science ®Google Scholar
• Chang SJ, Bristow RE, Ryu HS. Analysis of para-aortic lymphadenectomy up to the level of the renal vessels in apparent early-stage ovarian cancer. J Gynecol Oncol. 2013;24(1):29–36.
   PubMed Web of Science ®Google Scholar
• Jia X, Liu X, Li M, et al. Potential tumor suppressing role of microRNA-545 in epithelial ovarian cancer. Oncol Lett. 2018;15(5):6386–6392.
   PubMed Web of Science ®Google Scholar
• Shi J, Xu X, Zhang D, et al. Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression. J Ovarian Res. 2020;13(1):127.
   PubMed Web of Science ®Google Scholar
• Luo D, Liu D, Shi W, et al. PPA1 promotes NSCLC progression via a JNK- and TP53-dependent manner. Oncogenesis. 2019;8(10):53.
   PubMedGoogle Scholar
• Zhao S, Fan S, Shi Y, et al. Propranolol induced apoptosis and autophagy via the ROS/JNK signaling pathway in human ovarian cancer. J Cancer. 2020;11(20):5900–5910.
   PubMed Web of Science ®Google Scholar
• Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–156.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu X, Li T, et al. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncol Rep. 2017;37(5):3084–3092.
   PubMed Web of Science ®Google Scholar
• Cui XL, Wang XD, Lin SK, et al. Circular RNA circ_0067934 functions as an oncogene in glioma by targeting CSF1. Eur Rev Med Pharmacol Sci. 2019;23(19):8449–8455.
   PubMed Web of Science ®Google Scholar
• Zhao M, Ma W, Ma C. Circ_0067934 promotes non-small cell lung cancer development by regulating miR-1182/KLF8 axis and activating WNT/β-catenin pathway . Biomed Pharmacother. 2020;129:110461.
   PubMed Web of Science ®Google Scholar
• Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014;24(16):R762–76.
   PubMed Web of Science ®Google Scholar
• Sun J, Min H, Yu L, et al. The knockdown of LncRNA AFAP1-AS1 suppressed cell proliferation, migration, and invasion, and promoted apoptosis by regulating miR-545-3p/hepatoma-derived growth factor axis in lung cancer. Anticancer Drugs. 2021;32(1):11–21.
   PubMed Web of Science ®Google Scholar
• Luo D, Wang G, Shen W, et al. Clinical significance and functional validation of PPA1 in various tumors. Cancer Med. 2016;5(10):2800–2812.
   PubMed Web of Science ®Google Scholar
• Tomonaga T, Matsushita K, Yamaguchi S, et al. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin Cancer Res. 2004;10(6):2007–2014.
   PubMed Web of Science ®Google Scholar
• Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–549.
   PubMed Web of Science ®Google Scholar
• Tang Q, Yuan Q, Li H, et al. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin. Biochem Biophys Res Commun. 2018;497(3):827–834.
   PubMed Web of Science ®Google Scholar
• Huang HL, Chao MW, Li YC, et al. MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer. Sci Rep. 2016;6:31664.
   PubMed Web of Science ®Google Scholar
• Lin Z, Pan J, Chen L, et al. MiR-140 resensitizes cisplatin-resistant NSCLC cells to cisplatin treatment through the SIRT1/ROS/JNK pathway. Onco Targets Ther. 2020;13:8149–8160.
   PubMed Web of Science ®Google Scholar
• Xu Y, Lai Y, Weng H, et al. MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway . Aging (Albany NY)). 2019;11(9):2551–2564.
   PubMedGoogle Scholar
• Zhao T, Bai J, Zou Q, et al. Insulin in combination with cisplatin induces the apoptosis of ovarian cancer cells via p53 and JNK activation. Mol Med Rep. 2017;16(6):9095–9101.
   PubMed Web of Science ®Google Scholar
• Ji L, Zhong B, Jiang X, et al. Actin induces autophagy and apoptosis in human bladder cancer by potentiating ROS/JNK and inhibiting AKT pathways. Oncotarget. 2017;8(68):112498–112515.
   PubMedGoogle Scholar
• Wang S, Li H, Chen S, et al. Andrographolide induces apoptosis in human osteosarcoma cells via the ROS/JNK pathway. Int J Oncol. 2020;56(6):1417–1428.
   PubMed Web of Science ®Google Scholar